MedTrace Logo

Basal Tumours in Bladder Cancer, Response to chemoTherapy

NCT04089748 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 293

Last updated 2025-06-06

No results posted yet for this study

Summary

Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.

Conditions

Interventions

COMBINATION_PRODUCT

neoadjuvant chemotherapy with cisplatine

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Sponsors & Collaborators

  • Institut Curie

    collaborator OTHER

  • APHP

    collaborator OTHER

  • University Hospital, Rouen

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-27
Primary Completion
2019-04-29
Completion
2019-04-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04089748 on ClinicalTrials.gov